A larger audience than ASH

biopearl123 · Post by **biopearl123** » Tue Sep 20, 2022 4:50 pm

In the event that Geron is unable or chooses not to present MDS PIII data at ASH, which remains a distinct possibility, given the guidance of early January TLR, having a new molecular entity that opens a door to an entire new way of approaching hematologic malignancies will no doubt warrant a world wide debut. There is only one stage for this event that would be worthy of this kind of ground breaking agent. Not the Lancet, not Blood and their cousins but the venerable New England Journal of Medicine. The NEJM has a readership of one million health care specialists in virtually every country every week. It has a hard copy circulation of about 200,000/wk. not to mention digital subscriptions. It is the most respected and widely read medical journal in the world. ASH might have 21,000 or so attendees. That approach would not get the word out like a NEJM article. Could be why they will wait. I think Aron Feingold will be very busy. Best Wishes to all. bp

bucbeard · Post by **bucbeard** » Tue Sep 20, 2022 6:05 pm

I love the thought, Andrew!

I remain hopeful...it does feel as if things are more in motion than ever before.

Ryan · Post by **Ryan** » Thu Sep 22, 2022 1:30 am

True. ASH is more of a venerable market mover for biotech stocks, especially indies obviously, because one drug &/or one abstract can deliver a paradigm shift and thus a value / valuation shift…

In either case, my main thought was to point out the Imetelstat has 2 notable articles in NEJM in the past decade, so a follow-up after late stage clinical trial is complete for MDS seems inevitable:

https://www.nejm.org/doi/full/10.1056/nejmoa1503479

https://www.nejm.org/doi/full/10.1056/NEJMoa1310523

biopearl123 · Post by **biopearl123** » Thu Sep 22, 2022 7:45 am

Ryan, thank you for reposting these previous NEJM articles. We have discussed them at length in the past and were hoping for more (a hope that may yet be realized). It could be argued that it all started there with the ET and MF articles. (It certainly did NOT start with the Maui non presentation). Perhaps things will come full circle. January is not that far away now. I hope everyone has had a chance to review the information from Dr. Jamieson’s lab. Given the extraordinary success of Forty Seven, it is very encouraging to see a lab of this caliber involved in doing important Imetelstat research. The addition of the article on combination therapy in HL also quite encouraging. I, like Dr. Scarlett am trying to curb my enthusiasm. Things are looking pretty pretty good!. Regards to all, bp

ImetelChat

A larger audience than ASH

A larger audience than ASH

Re: A larger audience than ASH

Re: A larger audience than ASH

Re: A larger audience than ASH